CA2293504A1 - Utilisation d'antagonistes de leptine pour traiter le diabete - Google Patents

Utilisation d'antagonistes de leptine pour traiter le diabete Download PDF

Info

Publication number
CA2293504A1
CA2293504A1 CA002293504A CA2293504A CA2293504A1 CA 2293504 A1 CA2293504 A1 CA 2293504A1 CA 002293504 A CA002293504 A CA 002293504A CA 2293504 A CA2293504 A CA 2293504A CA 2293504 A1 CA2293504 A1 CA 2293504A1
Authority
CA
Canada
Prior art keywords
leptin
treatment
insulin
mice
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002293504A
Other languages
English (en)
Inventor
Valur Emilsson
Michael Anthony Cawthorne
Yong-Ling Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293504A1 publication Critical patent/CA2293504A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un antagoniste de leptine dans la fabrication d'un médicament permettant de traiter des troubles dûs à des carences insuliniques, à une hyperglycémie et à une résistance insulinique.
CA002293504A 1997-06-06 1997-06-06 Utilisation d'antagonistes de leptine pour traiter le diabete Abandoned CA2293504A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (fr) 1997-06-06 1997-06-06 Utilisation d'antagonistes de leptine pour traiter le diabete

Publications (1)

Publication Number Publication Date
CA2293504A1 true CA2293504A1 (fr) 1998-12-10

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293504A Abandoned CA2293504A1 (fr) 1997-06-06 1997-06-06 Utilisation d'antagonistes de leptine pour traiter le diabete

Country Status (9)

Country Link
EP (1) EP0986397A1 (fr)
JP (1) JP2002504102A (fr)
KR (1) KR20010013414A (fr)
AU (1) AU2951797A (fr)
CA (1) CA2293504A1 (fr)
HU (1) HUP0003428A3 (fr)
IL (1) IL133136A0 (fr)
TR (1) TR199902980T2 (fr)
WO (1) WO1998055139A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005211755B2 (en) 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (fr) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2416797A4 (fr) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Composés agonistes de l'amyline pour mammifères ayant une carence en strogènes
WO2012050925A2 (fr) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Leptines hautement solubles
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015153933A1 (fr) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Inhibiteurs hsp 90 pour le traitement de l'obésité et leurs procédés d'utilisation
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997002004A2 (fr) * 1995-06-30 1997-01-23 Eli Lilly And Company Procedes pour le traitement du diabete

Also Published As

Publication number Publication date
JP2002504102A (ja) 2002-02-05
TR199902980T2 (xx) 2000-05-22
AU2951797A (en) 1998-12-21
HUP0003428A3 (en) 2001-12-28
EP0986397A1 (fr) 2000-03-22
KR20010013414A (fr) 2001-02-26
IL133136A0 (en) 2001-03-19
HUP0003428A2 (hu) 2001-05-28
WO1998055139A1 (fr) 1998-12-10

Similar Documents

Publication Publication Date Title
CA2293504A1 (fr) Utilisation d'antagonistes de leptine pour traiter le diabete
Haffner et al. The role of behavioral variables and fat patterning in explaining ethnic differences in serum lipids and lipoproteins
Roman et al. Central leptin action improves skeletal muscle AKT, AMPK, and PGC1α activation by hypothalamic PI3K-dependent mechanism
Haynes et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice
Larsen et al. Differential influences of peroxisome proliferator–activated receptorsγ and-α on food intake and energy homeostasis
Caprio et al. Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations
Caprio et al. Metabolic impact of obesity in childhood
Baldelli et al. Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatment
Toste et al. Neonatal leptin treatment programmes leptin hypothalamic resistance and intermediary metabolic parameters in adult rat
Garcia-Vicente et al. Oral insulin-mimetic compounds that act independently of insulin
AU645076B2 (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
Bell-Anderson et al. Leptin as a potential treatment for obesity: progress to date
Henry et al. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors
US20080020974A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
Zhang et al. Aged-obese rats exhibit robust responses to a melanocortin agonist and antagonist despite leptin resistance
Wasan et al. Emerging pharmacological approaches to the treatment of obesity
US20040142868A1 (en) Method of treating liver steatosis in a mammal
Baltaci et al. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc
Judge et al. Prolonged hyperphagia with high-fat feeding contributes to exacerbated weight gain in rats with adult-onset obesity
US20040048773A1 (en) Use of leptin antagonists for the treatment of diabetes
CA2474964C (fr) Agent augmentant la sensibilite a l'insuline, qui contient de l'adiponectine
Liu et al. Basal and stimulated plasma leptin in diabetic subjects
Freedman et al. Effect of adrenalectomy on in vivo glucose metabolism in insulin resistant Zucker obese rats
Frittitta et al. High insulin levels do not influence PC‐1 gene expression and protein content in human muscle tissue and hepatoma cells
US20020002181A1 (en) Use of leptin antagonists for the treatment of diabetes

Legal Events

Date Code Title Description
FZDE Discontinued